Francesca Palandri/LinkedIn
Aug 17, 2026, 16:22
Francesca Palandri: Why Is Ruxolitinib Response So Heterogeneous in Myelofibrosis?
Francesca Palandri, Hematologist at IRCCS Sant’Orsola Polyclinic – Bologna University Hospital, shared on LinkedIn about a recent article she and Filippo Branzanti co-authored, published in Clinical Lymphoma Myeloma and Leukemia, adding:
”Why is ruxolitinib response so heterogeneous in myelofibrosis?
Our SOHO State of the Art review covers:
- Cytopenic vs. proliferative phenotype
- Dose intensity (the 1 modifiable factor)
- HMR mutations, RAS/CBL, cytogenetics
- Dynamic models RR6, iRR6, STR-PM
Moving from static baseline prognostication to response-driven precision medicine.”
Title: SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis
Authors: Francesca Palandri, Filippo Branzanti
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 2, 2026, 06:00Susan Wickersham: Gradual Shift towards Autologous Blood Transfusion is a Current Trend
-
Oct 2, 2026, 05:54Shamee Shastry: When Every Cell Reacts – The Hunt for Rare Blood
-
Oct 2, 2026, 05:49David Mclntosh: Expanding Plasma Protein Therapies in Underserved Regions
-
Oct 2, 2026, 05:38Dianne E. van der Wal: C-Terminal Endings Impact PAR1/PAR4 Peptide Potency in In Vitro Platelet Assays
-
Oct 2, 2026, 05:29Mohammed Alo: Your LDL Isn’t a Snapshot – It’s a Smoking Habit Measured in Years
-
Oct 2, 2026, 00:33Marwa Mostafa: Hemoglobinopathies – When Globin Genes Go Wrong
-
Oct 1, 2026, 23:46Behnood Bikdeli: Global Burden of Venous Thromboembolism
-
Oct 1, 2026, 23:46Sthanu Subramanian: Clinical Presentation, Risk Factors, Diagnosis, and Neuroimaging Findings in CVT
-
Oct 1, 2026, 23:45Martha Gulati: Oral MHT Is Associated With Increased Thrombotic Risk